Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing crohn's disease

Journal of Clinical Gastroenterology

Volumn 43, Issue 10, 2009, Pages 950-956

  Taxonera, Carlos ^a   Rodrigo, Luis ^g   Casellas, Francesc ^h,i   Calvet, Xavier ^i,j   Gómez Camacho, Federico ^k   Ginard, Daniel ^l   Castro, Manuel ^m   Castro, Luisa ⁿ   Ponce, Marta ^i,o   Martínez Montiel, Pilar ^b   Ricart, Elena ^c,i   Gisbert, Javier P ^d,i   Román, Antonio López San ^e   Morales, José M ^f   Casado, Miguel Á ^f  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e Hospital Ramóny Cajal   (Italy)

^f Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j Parc Taulí Health Corporation   (Spain)

^k Hospital Univeritario Reina Sofia   (Spain)

^l HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^m HOSPITAL UNIVERSITARIO DE VALME   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^o HOSPITAL UNIVERSITARIO LA FE   (Spain)

more..

Author keywords

Crohn's disease; Fistulizing; Infliximab; Luminal; Maintenance therapy; Resource use

Indexed keywords

CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CHRONIC DISEASE; CROHN DISEASE; HEALTH CARE UTILIZATION; HUMAN; IMMUNOTHERAPY; INTESTINE FISTULA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ADOLESCENT; ADULT; AGED; FEMALE; HEALTH CARE PLANNING; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICS; UTILIZATION REVIEW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 74949122798     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181986917     Document Type: Article

References (37)

1. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther. 2002;16:1603-1609.
2. Casellas F, Arenas JI, Baudet JS, et al. Impairment of healthrelated quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11:488-496.
3. Longobardi T, Jacobs P, Wu L, et al. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol. 2003;98: 844-849. (Pubitemid 36576312)
4. Feagan BG, Bala M, Yan S, et al. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol. 2005;39:390-395.
5. Probert CS, Jayanthi V, Wicks AC, et al. Mortality from Crohn's disease in Leicestershire 1972-1989: and epidemiological community based study. Gut. 1992;33:1226-1228.
6. Jess T, Loftus EV Jr, Harmsen WS, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006;55:1248-1254.
7. Wolters FL, Russel MG, Sijbrandij J, et al. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut. 2006;55:510-518.
8. Hay JW, Hay AR. Inflammatory bowel disease: costsof- illness. J Clin Gastroenterol. 1992;14:309-317.
9. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalizations in Crohn's disease. Am J Gastroenterol. 2000; 95:524-530.
10. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002;35:151-156.
11. Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol. 2005;17:1047-1052.
12. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128: 862-869.
13. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131:719-728.
14. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol. 1997; 32:1134-1139.
15. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol. 2000;95:1955-1960.
16. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med. 1997;337: 1029-1035.
17. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405. (Pubitemid 29205403)
18. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
19. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's desease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
20. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413. (Pubitemid 38182297)
21. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
22. Siddiqui MA, Scott LJ. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 2005;65: 2179-2208.
23. Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther. 2006;23:451-463.
24. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 (suppl A):5-36.
25. Wyke RJ, Edwards FC, Allan RN. Employment problems and prospects for patients with inflammatory bowel disease. Gut. 1998;29:1229-1235.
26. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49-57.
27. Bodger K. Cost of illness of Crohn's disease. Pharmacoeconomics. 2002;20:639-652.
28. Boonen A, Dagnelie PC, Feleus A, et al. The impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control study. Inflamm Bowel Dis. 2002;8:382-389.
29. Juan J, Estiarte R, Colome E, et al. Burden of illness of Crohn's disease in Spain. Dig Liver Dis. 2003;35:853-861.
30. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53:1471-1478.
31. Saro-Gismera C, de la Coba C, Casado MA, et al. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther. 2007;26:1313-1323.
32. Gisbert JP, Nino P, Cara C, et al. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther. 2008;28:228-238.
33. Colombel JF, Rutgeerts P, Reinisch W, et al. Sonic: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gut. 2008;57(suppl II):A1.
34. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91-96.
35. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442.
36. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006;55:i36-i58.
37. Lichtenstein GR, Abreu MT, Cohen R, et al. American gastroenterological association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. (Pubitemid 43374543)